access-principles-1access-principles-2access-principles-3backcarrierdevelopmentease_of_administrationexportimplantableinjectablenon-implantablenon_carriernon_injectableother_featuresprintroute_of_administrationtherapeutic_areatype_of_tech

Drug information

Drug's link(s)
Generic name

Dapivirine (DPV) subdermal implant

Brand names

Dapivirine subdermal implant

Compound type

Small molecule

Drug class/category

NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor)

Lifecycle status

Preclinical / IND

Summary

DPV implant is a silicone-based subdermal implant designed to provide sustained systemic delivery of DPV over extended periods. DPV prevents HIV replication by inhibiting reverse transcriptase. Unlike the approved vaginal ring, the implant delivers the drug systemically, requiring distribution to genital tissues to achieve protective concentrations. The implant exhibits near zero-order release kinetics, providing consistent drug exposure with minimal fluctuation. Initial reservoir implants released approximately 5-20 µg/day for more than 246-330 days, with modelling suggesting potential multi-year activity. Formulation optimisation significantly increased release rates. Liquid-core and dip-coated reservoir designs achieved 19.5-41 µg/day, while matrix implants reached up to 185 µg/day. Enhanced release was driven by reduced membrane thickness and improved DPV solubility within the formulation. Key strengths include ultra-long-acting delivery, tunable release profiles, established silicone implant technology, and the potential to improve adherence compared with daily oral PrEP.

Approval status

Under preclinical investigation

Regulatory authorities

Under preclinical investigation

Therapeutic area(s)

  • HIV
Use case(s)
  • Pre-Exposure Prophylaxis (PrEP)
  • Prevention

Administration route

Transdermal

Associated long-acting platforms

Polymeric implant

Use of drug

Ease of administration
  • Administered by a community health worker
  • Administered by a nurse
  • Administered by a specialty health worker
Frequency of administration
  • Yearly
User acceptance
Not provided

Dosage

Available dose and strength

Dose: 72-91 mg dapivirine per implant

Maximum dose

91 mg per implant

Recommended dosing regimen

No clinical dosing regimen has been established yet

Format

Not provided

Additional comments

Not provided

Dosage link(s)

Related entries

Compounds
Compare

Dapivirine (DPV)

Additional information

Not provided

Developer(s)

Queen's University Belfast
Originator
United Kingdom

Queen's University Belfast

Queen's University Belfast (QUB) is a historic public research institution located in the heart of Belfast, Northern Ireland. Founded in 1845, it is a member of the elite Russell Group of research-intensive universities and was recently named the UK University of the Year 2026 by the Good University Guide. The university is globally celebrated for its architectural beauty, most

Drug structure

Scale-up and manufacturing prospects

Scale-up prospects

Not provided

Tentative equipment list for manufacturing

Not provided

Manufacturing

Dapivirine implants were manufactured by dispersing DPV in silicone elastomer, filling medical-grade silicone tubing to form a drug reservoir, curing the formulation, and sealing the implant ends. Optimised designs incorporated Kolliphor® EL liquid cores or dip-coated silicone membranes to enhance release. Quality testing included dimensional analysis, drug loading verification, DSC characterisation, and long-term in vitro release studies. Materials needed: 1) Micronised DPV 2) Translucent platinum-cured silicone elastomer tubing 3) Polyvinyl chloride tubing 4) Kolliphor® EL 5) Tween® 80

Specific analytical instrument required for characterization of formulation

Waters Alliance e2695 High-performance liquid chromatography (HPLC) system coupled with a 2489 UV/Visible detector

Excipients & delivery device(s)

Proprietary excipients used

Not provided

Novel excipients or existing excipients at a concentration above Inactive Ingredient Database (IID) for the specified route of administration

Kolliphor EL (Cremophor EL)

Residual solvents used

Not provided

Delivery device(s)

Not provided

Safety, Efficacy and Evidence Summary

Safety

No human safety, tolerability, TEAE, SAE, or injection-site reaction data were reported yet

Efficacy

No direct efficacy data were reported, but the release rate studies show that the implant achieved sustained, near zero-order dapivirine release for 246-330 days, with optimised designs delivering up to 185 μg/day.

Evidence Summary

Clinical safety and efficacy of DPV subdermal implant remain unconfirmed and require evaluation in preclinical and human studies.

References and relevant studies

There are either no relevant patents or these were not yet submitted to LAPaL